WO2006127702A3 - Analogs of glycyl-prolyl-glutamate - Google Patents

Analogs of glycyl-prolyl-glutamate Download PDF

Info

Publication number
WO2006127702A3
WO2006127702A3 PCT/US2006/019909 US2006019909W WO2006127702A3 WO 2006127702 A3 WO2006127702 A3 WO 2006127702A3 US 2006019909 W US2006019909 W US 2006019909W WO 2006127702 A3 WO2006127702 A3 WO 2006127702A3
Authority
WO
WIPO (PCT)
Prior art keywords
analogs
gpe
invention include
glycyl
prolyl
Prior art date
Application number
PCT/US2006/019909
Other languages
French (fr)
Other versions
WO2006127702A2 (en
Inventor
Margaret Anne Brimble
Paul William Richard Harris
Frank Sieg
Original Assignee
Neuren Pharmaceuticals Ltd
Neuren Pharmaceuticals Inc
Margaret Anne Brimble
Paul William Richard Harris
Frank Sieg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuren Pharmaceuticals Ltd, Neuren Pharmaceuticals Inc, Margaret Anne Brimble, Paul William Richard Harris, Frank Sieg filed Critical Neuren Pharmaceuticals Ltd
Priority to EP06770950A priority Critical patent/EP1888618A4/en
Priority to JP2008513622A priority patent/JP2008545697A/en
Publication of WO2006127702A2 publication Critical patent/WO2006127702A2/en
Publication of WO2006127702A3 publication Critical patent/WO2006127702A3/en
Priority to US11/986,518 priority patent/US7863304B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Embodiments of this invention include novel analogs of Glycyl-Prolyl-Glutamate (GPE) and compositions containing such analogs of GPE. Of these, certain analogs have modified proline residues. Other embodiments of this invention include uses of analogs of GPE to protect neural cells from degeneration and/or death in response to injury or disease. Disorders treatable with compounds and compositions of this invention include hypoxia/ischemia, toxic injury, and chronic neurodegenerative disorders including Parkinson's disease.
PCT/US2006/019909 2001-05-24 2006-05-23 Analogs of glycyl-prolyl-glutamate WO2006127702A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP06770950A EP1888618A4 (en) 2005-05-23 2006-05-23 Analogs of glycyl-prolyl-glutamate
JP2008513622A JP2008545697A (en) 2005-05-23 2006-05-23 Glycyl-prolyl-glutamate analogues
US11/986,518 US7863304B2 (en) 2001-05-24 2007-11-20 Analogs of glycyl-prolyl-glutamate

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68381305P 2005-05-23 2005-05-23
US60/683,813 2005-05-23

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/314,424 Continuation-In-Part US7605177B2 (en) 2001-05-24 2005-12-20 Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/986,518 Continuation-In-Part US7863304B2 (en) 2001-05-24 2007-11-20 Analogs of glycyl-prolyl-glutamate

Publications (2)

Publication Number Publication Date
WO2006127702A2 WO2006127702A2 (en) 2006-11-30
WO2006127702A3 true WO2006127702A3 (en) 2007-06-14

Family

ID=37452742

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/019909 WO2006127702A2 (en) 2001-05-24 2006-05-23 Analogs of glycyl-prolyl-glutamate

Country Status (3)

Country Link
EP (1) EP1888618A4 (en)
JP (1) JP2008545697A (en)
WO (1) WO2006127702A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007106555A2 (en) * 2006-03-14 2007-09-20 Neuren Pharmaceuticals Limited Oral formulations of glycyl-2-methylprolyl-glutamate
US20100310543A1 (en) * 2007-07-06 2010-12-09 University Of Zurich Method of preventing and treating acute brain pathologies
US20100210567A1 (en) * 2007-09-11 2010-08-19 Dorian Bevec Use of a tuftsin as a therapeutic agent
WO2009039971A2 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of the peptide sfllr-oh and muramyl dipeptide as therapeutic agents
EP2665704A1 (en) * 2011-01-19 2013-11-27 Galapagos NV Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases
PT2667715T (en) * 2011-01-27 2017-10-19 Neuren Pharmaceuticals Ltd Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glutamic acid
SG187271A1 (en) * 2011-07-07 2013-02-28 Agency Science Tech & Res Anti-amyloidogenic, alpha-helix breaking ultra-small peptide therapeutic
AU2013352294A1 (en) * 2012-11-28 2015-07-09 Neuren Pharmaceuticals Limited Treatment of Autism Spectrum Disorders using glycyl-l-2-methylprolyl-l-glutamic acid
CN103275106B (en) * 2013-04-19 2015-09-30 暨南大学 A kind of indole alkaloid adduct and preparation method thereof and preparing the application in antitumor drug
CA3149633A1 (en) * 2019-08-05 2021-02-11 Neuren Pharmaceuticals Limited Compositions of trofinetide
GB202102709D0 (en) * 2021-02-25 2021-04-14 Univ Southampton Compounds
CN113135983B (en) * 2021-04-12 2022-06-24 四川大学华西医院 Antitumor compound and preparation method thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187906B1 (en) * 1997-08-11 2001-02-13 Aukland Uniservices Limited Methods to improve neural outcome

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE435852T1 (en) * 2001-05-24 2009-07-15 Neuren Pharmaceuticals Ltd GPE ANALOGUE AND PEPTIDOMIMETICS

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187906B1 (en) * 1997-08-11 2001-02-13 Aukland Uniservices Limited Methods to improve neural outcome

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1888618A4 *

Also Published As

Publication number Publication date
WO2006127702A2 (en) 2006-11-30
JP2008545697A (en) 2008-12-18
EP1888618A2 (en) 2008-02-20
EP1888618A4 (en) 2009-07-15

Similar Documents

Publication Publication Date Title
WO2006127702A3 (en) Analogs of glycyl-prolyl-glutamate
WO2006133396A3 (en) Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1) pathway
WO2007038610A3 (en) Use of natural products for treatment of neurological disorders
WO2007070434A3 (en) Fused aminopiperidines as dipeptidyl peptidase-4 inhibitors for the treatment or prevention of diabetes
WO2006127530A3 (en) Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2007061677A3 (en) Spirolactam aryl cgrp receptor antagonists
CA2651453C (en) 5'-modified bicyclic nucleic acid analogs
WO2007024993A3 (en) Fused aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2008064351A3 (en) (r)-n-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs
WO2008097596A3 (en) Nrf2 screening assays and related methods and compositions
WO2006078676A3 (en) Bicyclic pyrimidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2008030988A3 (en) Selectively targeted antimicrobial peptides and the use thereof
WO2006066079A3 (en) Pyridazinone compounds
WO2009133573A3 (en) A homeopathic formulation
WO2007068894A3 (en) Substituted diphenylethers, -amines, -sulfides and -methanes for the treatment of respiratory disease
WO2007075872A3 (en) Nitroimidazole compounds
WO2008132021A3 (en) Fungicide mixtures
WO2007092496A3 (en) 7,9-dihydro-purin-8-one and related analogs as hsp90-inhibitors
WO2007150001A8 (en) Pyrro[1,2-b]pyridazinone compounds
WO2008136865A3 (en) (s)-n-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs
WO2006078576A3 (en) Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease
WO2007022269A3 (en) Compounds and compositions as tpo mimetics
WO2007061692A3 (en) Spirolactam tricyclic cgrp receptor antagonists
WO2008073982A3 (en) 5,6-dihydro-1h-pyridin-2-one compounds
WO2006128143A3 (en) Hydantoin compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2008513622

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006770950

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU